Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation

Nicoletta Cieri; Sara Mastaglio; Giacomo Oliveira; Monica Casucci; Attilio Bondanza; Chiara Bonini

doi:10.1111/imr.12130

Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation

Nicoletta Cieri, Sara Mastaglio, Giacomo Oliveira, Monica Casucci, Attilio Bondanza, Chiara Bonini

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

Hematopoietic stem cell transplantation from a healthy donor (allo-HSCT) represents the most potent form of cellular adoptive immunotherapy to treat malignancies. In allo-HSCT, donor T cells are double edge-swords: highly potent against residual tumor cells, but potentially highly toxic, and responsible for graft versus host disease (GVHD), a major clinical complication of transplantation. Gene transfer technologies coupled with current knowledge on cancer immunology have generated a wide range of approaches aimed at fostering the immunological response to cancer cells, while avoiding or controlling GVHD. In this review, we discuss cell and gene therapy approaches currently tested in preclinical models and in clinical trials. Video podcast available: Go to www.immunologicalreviews.com to watch an interview with Guest Editor Dr Carl June.

Original language	English
Pages (from-to)	165-180
Number of pages	16
Journal	Immunological Reviews
Volume	257
Issue number	1
DOIs	https://doi.org/10.1111/imr.12130
Publication status	Published - Jan 2014

Keywords

Adoptive cellular immunotherapy
Allogeneic hematopoietic stem cell transplantation
CAR
Gene therapy
Suicide gene
TCR

ASJC Scopus subject areas

Immunology
Immunology and Allergy

Access to Document

10.1111/imr.12130

Cite this

@article{56f5a5f2c19f4ed0b8da6171f899fc64,

title = "Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation",

abstract = "Hematopoietic stem cell transplantation from a healthy donor (allo-HSCT) represents the most potent form of cellular adoptive immunotherapy to treat malignancies. In allo-HSCT, donor T cells are double edge-swords: highly potent against residual tumor cells, but potentially highly toxic, and responsible for graft versus host disease (GVHD), a major clinical complication of transplantation. Gene transfer technologies coupled with current knowledge on cancer immunology have generated a wide range of approaches aimed at fostering the immunological response to cancer cells, while avoiding or controlling GVHD. In this review, we discuss cell and gene therapy approaches currently tested in preclinical models and in clinical trials. Video podcast available: Go to www.immunologicalreviews.com to watch an interview with Guest Editor Dr Carl June.",

keywords = "Adoptive cellular immunotherapy, Allogeneic hematopoietic stem cell transplantation, CAR, Gene therapy, Suicide gene, TCR",

author = "Nicoletta Cieri and Sara Mastaglio and Giacomo Oliveira and Monica Casucci and Attilio Bondanza and Chiara Bonini",

year = "2014",

month = jan,

doi = "10.1111/imr.12130",

language = "English",

volume = "257",

pages = "165--180",

journal = "Immunological Reviews",

issn = "0105-2896",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation

AU - Cieri, Nicoletta

AU - Mastaglio, Sara

AU - Oliveira, Giacomo

AU - Casucci, Monica

AU - Bondanza, Attilio

AU - Bonini, Chiara

PY - 2014/1

Y1 - 2014/1

N2 - Hematopoietic stem cell transplantation from a healthy donor (allo-HSCT) represents the most potent form of cellular adoptive immunotherapy to treat malignancies. In allo-HSCT, donor T cells are double edge-swords: highly potent against residual tumor cells, but potentially highly toxic, and responsible for graft versus host disease (GVHD), a major clinical complication of transplantation. Gene transfer technologies coupled with current knowledge on cancer immunology have generated a wide range of approaches aimed at fostering the immunological response to cancer cells, while avoiding or controlling GVHD. In this review, we discuss cell and gene therapy approaches currently tested in preclinical models and in clinical trials. Video podcast available: Go to www.immunologicalreviews.com to watch an interview with Guest Editor Dr Carl June.

AB - Hematopoietic stem cell transplantation from a healthy donor (allo-HSCT) represents the most potent form of cellular adoptive immunotherapy to treat malignancies. In allo-HSCT, donor T cells are double edge-swords: highly potent against residual tumor cells, but potentially highly toxic, and responsible for graft versus host disease (GVHD), a major clinical complication of transplantation. Gene transfer technologies coupled with current knowledge on cancer immunology have generated a wide range of approaches aimed at fostering the immunological response to cancer cells, while avoiding or controlling GVHD. In this review, we discuss cell and gene therapy approaches currently tested in preclinical models and in clinical trials. Video podcast available: Go to www.immunologicalreviews.com to watch an interview with Guest Editor Dr Carl June.

KW - Adoptive cellular immunotherapy

KW - Allogeneic hematopoietic stem cell transplantation

KW - CAR

KW - Gene therapy

KW - Suicide gene

KW - TCR

UR - http://www.scopus.com/inward/record.url?scp=84890169660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890169660&partnerID=8YFLogxK

U2 - 10.1111/imr.12130

DO - 10.1111/imr.12130

M3 - Article

C2 - 24329796

AN - SCOPUS:84890169660

VL - 257

SP - 165

EP - 180

JO - Immunological Reviews

JF - Immunological Reviews

SN - 0105-2896

IS - 1

ER -

Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this